Stromal Therapeutics is the biotechnological spin-off from the Kantonsspital St.Gallen.
Stromal Therapeutics has raised $537K in total funding. The most recent round was Seed. The last funding was announced in January 2022.
Stromal Therapeutics's investors include BaseLaunch.
Stromal Therapeutics is headquartered in Basel, Switzerland.
Stromal Therapeutics is the biotechnological spin-off from the Kantonsspital St.Gallen.
Stromal Therapeutics is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Stromal Therapeutics — Funding & Investors." VCBacked, January 28, 2022, https://www.vcbacked.co/company/stromal-therapeutics. Accessed September 30, 2026.
VCBacked. (2022). Stromal Therapeutics — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/stromal-therapeutics
{{cite web |title=Stromal Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/stromal-therapeutics |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated